Mary Mullen, MD

Bio

Mary Mullen

I am a gynecologic oncologist and physician-scientist with a research focus on DNA damage repair and the molecular mechanisms driving resistance to platinum chemotherapy and PARP inhibitors in ovarian cancers. My work is centered on identifying biomarkers of response within the DNA damage response (DDR) pathway and developing novel therapeutic strategies to overcome resistance, particularly in homologous recombination–proficient tumors. I am especially interested in advancing new approaches to overcome therapy resistance in these cancers and am actively involved in early-phase clinical trial development.

As Director of the Gynecologic Oncology Biorepository at Washington University, I lead efforts to integrate patient-derived tumor models, genomic and functional profiling, and translational research to accelerate biomarker discovery and drug development. I serve as Translational Research Co-Chair for the NCI’s NRG Oncology Ovarian Cancer Committee and am a core member of several national initiatives focused on advancing precision medicine in gynecologic cancers. My overarching goal is to bridge basic science and clinical application to improve outcomes for patients with therapy-resistant disease.

Research

Our lab is leading several projects aimed at developing clinically translatable biomarkers and therapies to improve outcomes for women with ovarian cancer. We are actively refining and validating functional biomarkers of homologous recombination (HR) proficiency and replication stress, using patient-derived tumor models and clinical specimens to predict response to platinum chemotherapy and PARP inhibitors. In parallel, we are conducting high-throughput functional screens to identify novel therapeutic targets capable of overcoming platinum resistance, particularly in HR-proficient tumors. We then mechanistically define the role of these targets in the DNA damage response (DDR) and leverage these insights to guide the rational design of therapeutic inhibitors and early-phase clinical trials. Together, these efforts are grounded in a strong commitment to translational science, with the ultimate goal of informing clinical decision-making and advancing new treatment strategies for patients with therapy-resistant ovarian cancer.

Recent publications 

Peer Reviewed Manuscripts/Abstracts:

Reagan M, DeBaun M, Frei-Jones M. Multi-modal intervention of inpatient management of pain significantly decrease the rate of acute chest syndrome. Pediatric Blood and Cancer 2011 Feb; 56(2):262-266. PMID: 21157894.

Reagan M, Xu H, Shih S, Secura G, Peipert J. A randomized trial of home versus clinic-based STD screening among men. Sexually Transmitted Diseases 2012 Nov; 39(11):842-847. PMID: 230064532.

Mullen M, Divine L, Hagemann I, Babb S, Powell M. Endometrial adenosarcoma in the setting of a germline DICER1 mutation: A case report. Gynecologic Oncology Reports 2017 Apr; 20:121-124. PMID 28459098

Kuroki L, Mullen M, Massad S, Wu N, Liu J, Mutch D, Powell M, Hagemann A, Thaker P, McCourt C, Novetsky A. Wound Complication Rates After Staples or Suture for Midline Vertical Skin Closure in Obese Women: A Randomized Controlled Trial. Obstetrics and Gynecology 2017 Jul;130(1):91-99. PMID: 28594761.

Palisoul M, Mullen M, Feldman R, Thaker P. Identification of molecular targets in vulvar cancers. Gynecologic Oncology 2017 Aug; 146(2):305-313. PMID: 28536037.

Mullen M, Kuroki L, Hunt S, Mutch D. A transperineal approach to hysterectomy of a retained didelphic uterine horn: A case report. Obstetrics and Gynecology 2017 Sep;130(3):561-564. PMID: 28796686.

Mullen M, Divine L, Porcelli B, Wilkinson-Ryan I, Dans M, Massad S, Powell M, Mutch M, Hagemann A, Thaker P. The effect of a multidisciplinary palliative care initiative on end of life care in gynecologic oncology patients. Gynecologic Oncology 2017 Nov;147(2):460-464. PMID: 28784245.

Smith S, Arudra S, Mullen M, Palisoul M, Dahiya S, Rao P, Thaker P. A rare case of endometrial cancer metastatic to the uveal choroid. Gynecologic Oncology Reports 2018 Feb; 23:24-27. PMID: 29326973.

Mullen M, Kuroki L, Thaker P. Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review. Gynecologic Oncology 2019 Feb;152(20):416-425. PMID: 30409489.

Mullen M, Mutch D. Dose low-dose aspirin decrease a women’s risk of ovarian cancer?: Examining the evidence. OBG Management 2018 Dec;30(12):20-22.

Mullen M, Mutch D. Should we abandon minimally invasive surgery for cervical cancer? OBG Management 2019 Jan;31(1):29-32,34.

Mullen M, Merfeld E, Palisoul M, Massad L, Woolfolk C, Powell M, Mutch D, Thaker P, Hagemann A, Kuroki L. Wound complication rates after vulvar excisions for premalignant lesions. Obstetrics and Gynecology 2019 Apr;133(4):658-665. PMID: 30870300.

Mullen M, Mutch D. Endometrial tumor immune response: a potential biomarker predictive of response to immunotherapy. Clinical Cancer Research 2019 Apr;25(8):2366-68.

Mullen M, Porcelli B, Cripe J, Kuroki L, Novetsky A, Massad L, Wan L, Powell M, Mutch D, Thaker P. Modified frailty index is predictive of wound complications in obese patients undergoing a midline vertical incision. Gynecologic Oncology 2020 Apr;157(1):287-292. PMID: 32001077.

Mullen M, Lomonosova E, Toboni M, Noia H, Wilke D, Oplt A, Guo L, Kuroki L, Hagemann A, McCourt C, Thaker P, Mutch D, Powell M, Fuh K. Effect on response to neoadjuvant chemotherapy in high-grade serous ovarian cancer by inhibiting the GAS6/AXL pathway and inducing homologous recombination deficiency. Journal of Clinical Oncology. 2020 May: 38 (suppl; abstr 6080).

Fuh K, Mullen M, Blachut B, Stover E, Konstantinopoulos P, Liu J, Matulonis U, Khabele D, Mosammaparast N, Vindigni A. Homologous Recombination Deficiency Real-Time Clinical Assays, Ready or Not?. Gynecologic Oncology 2020 Dec;159(3):877-886. PMID: 32967790.

Gressel G, Marcus J, Mullen M, Sinno, A. Direct oral anticoagulant use in gynecologic oncology: A Society of Gynecologic Oncology Clinical Practice Statement. Gynecologic Oncology. 2021 Jan;160(1):312-321. PMID: 33257014.

Carey-Love A, Mullen M, Zamorano A, Markovina S, Hagemann AR, Fuh KC, Thaker PH, Mutch DB, Powell MA, Kuroki LM. The role of endometrial sampling for surveillance of recurrence in postmenopausal patients with medically inoperable stage I endometrial cancer. Gynecologic Oncology Reports. 2020 Dec 31:35;100694. PMID: 33490354.

Mullen M, McKinnish T, Fiala M, Zamorano A, Kuroki L, Fuh K, Hagemann A, McCourt C, Mutch D, Powell M, Wildes T, Thaker P. A Deficit-Accumulation Frailty Index Predicts Survival Outcomes in Patients with Gynecologic Malignancy. Gynecologic Oncology. 2021 Jun;161(3):700-704. PMID: 33648746.

Fuh K, Herzog T, Moore K, Myers T, Rimel B, Liu J, Alvarez Secord A, Hamilton E, Reid T, Lewin S, Mullen M, Mills K, Anderson R, Rangwala R. A phase 3, randomized, double-blind, adaptive, placebo/paclitaxel-controlled study of AVB-S6-500 in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/ENGOT OV-66/AVB-500-OC-004). Journal of Clinical Oncology. 2021 May: 15 (suppl; abstr TPS5605).

Polnaszek B, Mullen M, Bligard K, Raghuraman N, Massad LS. Term pregnancy after complete response of placental site trophoblastic tumor to immunotherapy. Obstetrics and Gynecology. A case report. Obstetrics and Gynecology 2021 July;138(1):115-118. PMID: 34259474.

Mullen M, Lomonosova E, Toboni M, Oplt A, Cybulla E, Blachut B, Peinan Zhao, Noia H, Wilke D, Rankin E, Kuroki L, Hagemann A, Hagemann I, McCourt C, Thaker P, Mutch D, Powell M, Mosammaparast N, Vindigni A, Fuh K. GAS6/AXL inhibition enhances ovarian cancer sensitivity to chemotherapy and PARP inhibition through increased DNA damage and enhanced replication stress. Molecular Cancer Research 2022 Feb;20(2):265-279. PMID: 34670865.

Toboni M, Lomonosova E, Bruce S, Tankou J, Mullen M, Schab A, Oplt A, Noia H, Wilke D, Kuroki L, Hagemann A, McCourt C, Thaker P, Powell M, Khabele D, Mutch D, Fuh K. Inhibition of AXL and VEGF-A has improved therapeutic efficacy in uterine serous cancer. Cancers 2021 Nov 23;13(23):5877. PMID: 34884986.

Bruce S, Huysman B, Bharucha J, Massad S, Mullen M, Hagemann A, Fuh K, McCourt C, Thaker P, Khabele D, Powell M, Mutch D, Kuroki L. Impact of the COVID-19 pandemic on referral to and delivery of gynecologic oncology care. Gynecologic Oncology Reports 2022 Feb;39:100928. PMID: 35024405.

Bruce S, Cho K, Noia H, Lomonosova E, Stock E, Oplt A, Blachut B, Mullen M, Kuroki L, Hagemann A, McCourt C, Thaker P, Khabele D, Powell M, Mutch D, Shriver L, Patti G, Fuh K. GAS6-AXL inhibition by AVB-500 overcomes resistance to paclitaxel in endometrial cancer by decreasing tumor cell glycolysis. Molecular Cancer Therapeutics 2022 Aug 2;21(8):1348-1359. PMID: 35588308.

Zamorano S, Mazul A, Marx C, Mullen M, Greenwade M, Massad L, McCourt C, Hagemann A, Thaker P, Fuh K, Powell M, Mutch D, Khabele D, Kuroki L. Community access to primary care is an important geographic disparity among ovarian cancer patients undergoing cytoreductive surgery. Gynecologic Oncology Reports 2022 Dec;44:101075.

Buckley M, Mullen M, Nizamuddin R, Stein J, Kuroki L, Fuh K, Hagemann A, McCourt C, Mutch D, Khabele D, Powell M, Ippolito J, Thaker P. High visceral fat to subcutaneous fat ratios portend a poor prognosis in patients with advanced endometrial cancer. Gynecologic Oncology 2022 Dec;167(3):96-401. PMID: 36180305.

Graham O, Rodriguez J, van Biljon L, Fashemi B, Graham E, Fuh K. Khabele D, Mullen M. Generation and Culturing of High-Grade Serous Ovarian Cancer Patient-Derived Organoids. J. Vis. Exp. 2023 Jan 6;(191). PMID: 36688549.

van Biljon, Fashemi B, Rodriguez J, Graham O, Compadre A, Fuh K, Khabele D, Mullen M. Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian cancer Organoids via Immunofluorescence Assays. J. Vis. Exp. 2023 Feb 24;(192). PMID: 36912550.

Kotnik E, Mullen M, Spies N, Tiandao L, Inkman M, Zhang J, Martins-Rodrigues F, Hagemann I, McCourt C, Thaker P, Hagemann A, Powell M, Mutch D, Khabele D, Mardis E, Longmore G, Maher C, Miller C, Fuh K. Genetic Characterization of Primary and Metastatic Tumors with Survival in High-Grade Serous Ovarian Cancer. Communications Biology. 2023 Jul 3;6(1):688. PMID: 37400526.

Compadre AJ, van Biljon L, Valentine M, Llop-Guevara A, Graham E, Fashemi B, Herencia-Ropero A, Kotnik E, Cooper I, Harrington S, Kuroki L, McCourt C, Hagemann A, Thaker P, Mutch D, Powell M, Sub L, Mosammaparast N, Serra V, Zhao P, Lomonosova E, Khabele D, Mullen M. RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer. Clin Cancer Res. 2023 Jul 5;29(13):2466-2479. PMID 37097615.

Schab A, Greenwade M, Lomonosova E, Cho K, Grither W, Noia H, Wilke D, Mullen M, Hagemann A, Hagemann I, Thaker P, Kuroki L, McCourt C, Khabele D, Powell M, Mutch D, Zhao P, Shriver L, Patti G, Longmore G, Fuh K. Stromal DDR2 promotes ovarian cancer metastasis through regulation of metabolism and secretion of extracellular matrix proteins. Mol Cancer Res. 2023 Nov 1;21(11):1234-1248. PMID: 37527178.

Grither W, Hageman I, Powell M, Mullen M. Attack of the clones: Unveiling subclonal/heterogenous mismatch repair (MMR)/microsatellite instability (MSI) status in endometrial cancer (EC). Cancer. 2023 Oct. PMID: 37902951.

Fashemi B, van Biljon L, Rodriguez J, Graham O, Mullen M, Khabele D. Ovarian cancer patient-derived organoid models for pre-clinical drug testing. J. Vis. Exp. 2023 Sep 15;(199). PMID: 37782106.

Whelan K, Dillon M, Strickland K, Pothuri B, Bae-Jump P, Borden L, Thaker P, Haight P, Arend R, Ko E, Jackson A, Corr B, Ayoola-Adeola M, Wright J, Podwika S, Smitherman C, Thomas S, Lightfoot M, Newton M, Washington C, Mullen M, Cosgrove C, Harsono A, Powell K, Herzog T, Salani R, Secord A. TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes. Gynecol Oncol. 2023 Nov;178:44-53. PMID: 37748270.

Graham O, Rodriguez J, Abbott R, Lomonosova E, Fashemi B, Drexler R, Grither W, Rodriguez K, Compadre A, Loeb M, Sanders B, Kuroki L, Hagemann A, McCourt C, Thaker P, Fuh K, Powell M, Hagemann I, Mutch D, Khabele D, Mullen M. A toolkit for a modern gynecologic oncology tissue bank. Gynecol Oncol. 2024 Oct;189:1-8. PMID: 38971004.

Mullen M, Grither W, Millimet H, Mutch D, Hagemann A, McCourt C, Powell M, Thaker P, Khabele D, Kuroki L. Prophylactic antibiotics for excision of premalignant vulvar lesions: A pilot randomized controlled trial. Gynecol Oncol Rep. 2024 Aug8;55:101476. PMID: 39229484.

Mo C, Liu J, Chen S, Storrs E, Costa A, Houston A, Wendl M, Jayasinghe R, Iglesia M, Ma C, Herndon J, Southard-Smith A, Liu X, Mudd J, Karpova A, Shinkle A, Goedegebuure S, Abdelzaher A, Bo P, Fulghum L, Livingston S, Balaban M, Hill A, Ippolito J, Thorsson V, Held J, Hagemann I, Kim E, Boyguinov P, Kim A, Mullen M, Shoghi K, Ju T, Reimers M, Weimholt C, Kang L, Puram S, Veis D, Pachynski R, Fuh K, Chheda M, Gilanders W, Fields R, Raphael B, Chen F, Ding L. Tumor evolution and microenvironment interactions in 2D and 3D space. Nature. October 2024;634(8036):1178-1186. PMID: 39478210.

Davenport J, Tran T, Harris B, Fingerman D, DeWeerd R, Elkhidir L, LaVigne D, Fuh K, Sun L, Bednarski J, Drapkin R, Mullen M, Green A. APOBEC3A drives ovarian cancer metastasis by altering epithelial-to-mesenchymal transition. JCI Insight. In press.

Sanchez M, Thomas S, Smitherman C, Cosgrove C, Bae-Jump V, Crafton S, Hacker K, Ko E, Krivak T, Lara O, Moore K, Mullen M, Pothuri B, Thaker P, Washington C, Arend R, Corr B, Duska L, Jackson A, Konecny G, Wright J, Alvarez Secord A, Backes F. Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort study. Gyn Onc. In press.


Book Chapters:

Mullen M, Cripe J, Thaker P. Palliative Care in Gynecologic Oncology. Obstetrics and Gynecology Clinics. New York, NY: Elsevier, 2019. Print.

Mullen M, Noia H, Fuh K. Culturing Primary Human Mesothelial Cells. Methods in Molecular Biology: Ovarian Cancer. Totowa, NJ: Humana Press, 2021. Text in Print.

Oral Presentations:

Mullen M, Divine L, Porcelli B, Wilkinson-Ryan I, Dans M, Massad S, Powell M, Mutch M, Hagemann A, Thaker P. The effect of a multidisciplinary palliative care initiative on end of life care in gynecologic oncology patients. The Society of Gynecologic Oncology 48th Annual Meeting on Women’s Cancer. Washington, DC. March 2017.

Mullen M, Divine L, Porcelli B, Wilkinson-Ryan I, Dans M, Massad S, Powell M, Mutch M, Hagemann A, Thaker P. The effect of a multidisciplinary palliative care initiative on end of life care in gynecologic oncology patients. The Annual David Rothman Resident Research Day. Washington University in St. Louis, Department of Obstetrics and Gynecology. St. Louis, MO. April 2017.

Mullen M, Lomonosova E, Beck H, Wilke D, Guo L, Kuroki L, Hagemann A, McCourt C, Thaker P, Mutch D, Powell M, Fuh K. Therapeutic AXL/GAS6 inhibition of tumor and stromal cells increases DNA damage and improves response to chemotherapy in ovarian cancer. The Society of Gynecologic Oncology 50th Annual Meeting on Women’s Cancer. Honolulu, HI. March 2019.

Mullen M, Lomonosova E, Beck H, Wilke D, Guo L, Kuroki L, Hagemann A, McCourt C, Thaker P, Mutch D, Powell M, Fuh K. Therapeutic AXL/GAS6 inhibition of tumor and stromal cells increases DNA damage and improves response to chemotherapy in ovarian cancer. The Annual David Rothman Resident Research Day. Washington University in St. Louis, Department of Obstetrics and Gynecology. St. Louis, MO. April 2019.

Mullen M, Lomonosova E, Beck H, Wilke D, Guo L, Kuroki L, Hagemann A, McCourt C, Thaker P, Mutch D, Powell M, Fuh K. Therapeutic AXL/GAS6 inhibition of tumor and stromal cells increases DNA damage and improves response to chemotherapy in ovarian cancer. St. Louis Obstetrics and Gynecology Symposium. St. Louis, MO. May 2019.

Mullen M, Lomonosova E, Toboni M, Oplt A, Cybulla E, Blachut B, Noia H, Wilke D,  Rankin E, Kuroki L,   Hagemann A, Hagemann I,  McCourt C, Thaker P, Mutch D,   Powell M, Mosammaparast N, Vindigni A, Fuh K. Inducing carboplatin sensitivity with GAS6/AXL inhibition through increased replication stress. The Society of Gynecologic Oncology 52nd Annual Meeting on Women’s Cancer. Virtual Meeting. March 2021.

Mullen M, Lomonosova E, Toboni M, Oplt A, Cybulla E, Blachut B, Noia H, Wilke D,  Rankin E, Kuroki L,   Hagemann A, Hagemann I,  McCourt C, Thaker P, Mutch D,   Powell M, Mosammaparast N, Vindigni A, Fuh K. GAS6/AXL inhibition enhances ovarian cancer sensitivity to carboplatin and olaparib through increased DNA damage and enhanced replication stress. Washington University in St. Louis School of Medicine DNA Damage, Metabolism, and Repair Seminar Series. October 2021.

Mullen M, van Biljon L, Quinn J, Greenwade M, Opara G, Noia H, Hagemann I, Hagemann A, Kuroki L, McCourt C, Thaker P, Powell M, Mutch D, Khabele D, Fuh K. Tumor and stromal AXL expression regular ovarian cancer metastasis. The Society of Reproductive Investigation 69th Annual Scientific Meeting. Denver, CO. March 2022.

Fashemia B, van Biljon L, Kuroki L, Hagemann A, McCourt C, Thaker P, Massad S, Mutch D, Powell M, Fuh K, Mullen M, Khabele D. Patient-Derived Ovarian Cancer Organoid Living Tissue Bank. The Society of Reproductive Investigation 69th Annual Scientific Meeting. Denver, CO. March 2022.

Secord A, Pothuri B, Backes F, Thaker P, Gehrig P, Previs R, Borden L, Thomas S, Jackson A, Konecny G, Duska L, Arena R, Wright J, Corr B, Maxwell G, Cosgrove C, Mullen M, Moore K, Herzog TJ, Cohen J, Gockley A, Gaillard S, Nickles Fader A, Berchuck A, Bae-Jump V. Genomic Alterations, molecularly targeted therapy and race: Real world data from endometrial Cancer Molecularly Targeted Therapy Consortium. The Society of Gynecologic Oncology 53rd Annual Meeting on Women’s Cancer. Phoenix, AZ. March 2022.

Van Biljon L, Fashemi B, Blachut B, Cooper I, Kuroki L, McCourt C, Hagemann A, Thaker P, Massad S, Powell M, Mutch D, Khabele D, Fuh K, Mullen M. Rad51 is a biomarker predictive of homologous recombination deficiency and clinical response to DNA damaging agents in patient-derived ovarian cancer organoids. The Annual David Rothman Resident Research Day. Washington University in St. Louis, Department of Obstetrics and Gynecology. St. Louis, MO. April 2022.

Fashemi B, van Biljon L, Gupta V, Woodard T, Graham O, Rodriquez J, Kuroki L, Hagemann A, McCourt C, Thaker P, Mutch D, Powell M, Mullen M, Bitler B, Khabele D. Developing Patient and Murine Derived Organoid Models of Ovarian Cancer. Washington University Center for Reproductive Health Sciences. St. Louis, MO. January 2023.

Turner K, Bruce S, Carbonell K, Mullen M, Hagemann A, McCourt C, Thaker P, Khabele D, Powell M, Mutch D, Massad LS, Kuroki L. Two-year follow-up on the impact of the COVID-19 pandemic on outcomes in gynecologic oncology patients. The Annual David Rothman Resident Research Day. Washington University in St. Louis, Department of Obstetrics and Gynecology. St. Louis, MO. April 2023.

Fashemi B, van Biljon L, Gupta V, Woodard T, Graham O, Rodriguez J, Kuroki L, Hagemann A, McCourt C, Thaker P, Mutch D, Powell M, Mullen M, Bitler B, Khabele D. Developing patient-derived and murine organoid models of ovarian cancer. The Annual David Rothman Resident Research Day. Washington University in St. Louis, Department of Obstetrics and Gynecology. St. Louis, MO. April 2023.

Fashemi B, van Biljon L, Gupta V, Woodard T, Graham O, Rodriguez J, Kuroki L, Hagemann A, McCourt C, Thaker P, Mutch D, Powell M, Bitler B, Mullen M, Khabele D. Olaparib combined with entinostat exerts differential effects on tumor-associated macrophages in tumors compared to ascites in syngeneic HR-proficient murine models of ovarian cancer. The Society for Gynecologic Oncology 54th Annual Meeting on Women’s Cancer. Tampa, FL. March 2023.

Compadre A, van Biljon L, Valentine M, LlopGuevara A, Graham E, Fashemi B, Herencia-Ropero A, Kotnik E, Cooper I, Harrington S, Kuroki L, McCourt C, Hagemann A, Thaker P, Mutch D, Powell M, Sun L, Mosammaparast N, Serra V, Zhao P, Lomonosova E, Khabele D, Mullen M. RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer. The Annual David Rothman Resident Research Day. Washington University in St. Louis, Department of Obstetrics and Gynecology. St. Louis, MO. April 2023.

Compadre A, van Biljon L, Valentine M, Llop-Guevara A, Graham E, Fashemi B, Herencia-Ropero A, Kotnik E, Cooper I, Harrington S, Kuroki L, McCourt C, Hagemann A, Thaker P, Mutch D, Powell M, Sun L, Mosammaparast N, Serra V, Zhao P, Lomonosova E, Khabele D, Mullen M. RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer. Center for Genome Integrity Spring Retreat. St. Louis, MO. May 2023.

Compadre D, Sandoval C, Rodriguez K, Kuroki L, McCourt C, Hagemann A, Premal H. Thaker P, Powell M, Mutch D,  Hagemann I,  Fuh K, Sun L, Zhao P, Verma P, Khabele D, Lomonosova E, Mullen M.  A combined RAD51 and phosphorylated replication protein A2 assay predicts response to platinum chemotherapy in high-grade serous ovarian cancer. The Society for Gynecologic Oncology 55th Annual Meeting on Women’s Cancer. San Diego, CA. March 2024.

Rodriguez, K, Loeb M, Minnett M, Lomonosova E, Brown J, Schab A, Sandoval Pacheco C, Van Biljon L, Oplt A, Drexler R, Sanders B, Kuroki L, McCourt C, Hagemann A, Hagemann I, MD, Thaker P, Mutch D, Powell M, Mosammaparast N, Verma P, Fuh K, Khabele D, Mullen M. COPS5 inhibition targets nucleotide excision repair and homologous recombination to synergize with platinum chemotherapy. 15th Biennial Ovarian Cancer Research Symposium presented by Rivkin Center for Ovarian Cancer Research and the American Association for Cancer Research. Seattle, WA. Sep 2024.

Rodriguez K, Sandoval Pacheco C, Lomonosova E, Loeb M, Minett M, Van Biljon L, Kuroki L, MD, McCourt C, Hagemann A, Hagemann I, Thaker P, Mutch D, Powell M, Fuh K, Verma P, Mosammaparast N, Khabele D, Mullen M . COPS5 inhibition enhances platinum chemotherapy response by targeting DNA damage repair. Center for Genome Integrity Retreat. New Heaven, MO. March 2024.